IRIS
FORMISANO, LUIGI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.313
EU - Europa 3.070
NA - Nord America 2.928
SA - Sud America 413
AF - Africa 110
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 4
Totale 10.846
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.813
SG - Singapore 1.771
RU - Federazione Russa 1.297
IT - Italia 916
CN - Cina 898
VN - Vietnam 834
BR - Brasile 321
HK - Hong Kong 320
DE - Germania 216
FR - Francia 143
IN - India 131
NL - Olanda 114
FI - Finlandia 108
JP - Giappone 82
CA - Canada 70
GB - Regno Unito 65
KR - Corea 59
IE - Irlanda 49
AR - Argentina 48
CI - Costa d'Avorio 43
PK - Pakistan 31
UA - Ucraina 29
MX - Messico 27
PH - Filippine 26
SE - Svezia 26
BD - Bangladesh 25
PL - Polonia 25
IQ - Iraq 23
ZA - Sudafrica 23
ES - Italia 16
BE - Belgio 15
TR - Turchia 15
VE - Venezuela 14
AT - Austria 13
MY - Malesia 12
UZ - Uzbekistan 12
ID - Indonesia 11
TH - Thailandia 11
EC - Ecuador 10
LT - Lituania 10
EG - Egitto 9
TN - Tunisia 8
AU - Australia 7
IR - Iran 7
PY - Paraguay 7
CL - Cile 6
ET - Etiopia 6
MA - Marocco 6
AZ - Azerbaigian 5
CO - Colombia 5
GR - Grecia 5
IL - Israele 5
SA - Arabia Saudita 5
CZ - Repubblica Ceca 4
NP - Nepal 4
TW - Taiwan 4
AE - Emirati Arabi Uniti 3
BG - Bulgaria 3
KE - Kenya 3
MK - Macedonia 3
NI - Nicaragua 3
OM - Oman 3
XK - ???statistics.table.value.countryCode.XK??? 3
AL - Albania 2
BZ - Belize 2
CR - Costa Rica 2
DZ - Algeria 2
GE - Georgia 2
GT - Guatemala 2
JM - Giamaica 2
JO - Giordania 2
KG - Kirghizistan 2
KZ - Kazakistan 2
PA - Panama 2
PT - Portogallo 2
RS - Serbia 2
YT - Mayotte 2
AM - Armenia 1
AO - Angola 1
BF - Burkina Faso 1
BJ - Benin 1
BS - Bahamas 1
BY - Bielorussia 1
CG - Congo 1
CY - Cipro 1
DO - Repubblica Dominicana 1
EE - Estonia 1
EU - Europa 1
HN - Honduras 1
HU - Ungheria 1
KN - Saint Kitts e Nevis 1
KW - Kuwait 1
LB - Libano 1
MN - Mongolia 1
MT - Malta 1
NZ - Nuova Zelanda 1
PE - Perù 1
PS - Palestinian Territory 1
QA - Qatar 1
RO - Romania 1
Totale 10.837
Salva come PNG Salva come JPEG
Città #
Singapore 900
San Jose 496
Naples 324
Hong Kong 310
Moscow 301
Ashburn 290
Hefei 280
Ho Chi Minh City 251
Beijing 241
Chandler 204
Hanoi 184
Dallas 179
Santa Clara 126
Napoli 103
Amsterdam 87
Munich 87
Lauterbourg 82
The Dalles 77
Tokyo 71
Los Angeles 60
Seoul 51
Kochi 50
New York 48
Millbury 45
Turku 45
Redondo Beach 41
Buffalo 38
Des Moines 38
Boston 37
Da Nang 37
Haiphong 36
Helsinki 36
São Paulo 34
Hicksville 32
Nanjing 31
Rome 31
Council Bluffs 28
Princeton 27
Frankfurt am Main 25
Lawrence 24
Falkenstein 23
Pune 22
Montreal 20
Nuremberg 20
Seattle 19
Toronto 19
Brooklyn 18
Houston 18
Orem 18
San Mateo 18
Wilmington 17
Chicago 16
Dong Ket 16
Milan 16
Warsaw 16
Lahore 15
Stockholm 15
London 14
Ottawa 14
Caserta 13
Dublin 13
Formia 13
Hải Dương 13
Mexico City 13
Ninh Bình 13
Biên Hòa 12
Can Tho 12
Chennai 12
Johannesburg 12
Salt Lake City 11
Brussels 10
Hebei 10
Nanchang 10
Tashkent 10
Casoria 9
Denver 9
Poplar 9
Rio de Janeiro 9
Shanghai 9
Turin 9
Woodbridge 9
Kuala Lumpur 8
Modica 8
Nha Trang 8
Porto Alegre 8
Redwood City 8
Thái Nguyên 8
Tianjin 8
Afragola 7
Angri 7
Ankara 7
Baghdad 7
Belo Horizonte 7
Changsha 7
Guangzhou 7
Guayaquil 7
Manchester 7
Palma Campania 7
Phoenix 7
Thái Bình 7
Totale 6.101
Salva come PNG Salva come JPEG
Nome #
Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors 208
CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors. 177
Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer 162
C-Src and EGFR inhibition in molecular cancer therapy: What else can we improve? 161
1599P - Effects of Hedgehog signaling inhibition on epithelial-stromal interactions in triple negative breast cancer cells 160
Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review. 158
Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status 157
Everolimus induces Met inactivation by disrupting the FKBP12/Met complex 157
Evaluation of exercise capacity by means of cardiopulmonary exercise testing (CPET) in older adult cancer patients undergoing antineoplastic treatments 154
Metastasis-Directed Stereotactic Body Radiotherapy in Prostate Cancer Patients Treated with Systemic Therapy and Undergoing Oligoprogression: Report on 11 Consecutive Cases 152
Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis. 152
Increased anaerobic metabolism is a distinctive signature in a colorectal cancer cellular model of resistance to anti-epidermal growth factor receptor antibody 150
Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 era 149
FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules 148
Use of folfirinox or nab-paclitaxel plus gemcitabine for the treatment of locally advanced pancreatic adenocarcinoma: A single institution observational study 148
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients 148
Prevention of cardiovascular complications in elderly cancer patients 148
Evaluation of the Molecular Landscape in PD-L1 Positive Metastatic NSCLC: Data from Campania, Italy 146
Role of sphingosine kinase 1 (SphK1) on cetuximab resistance in colorectal cancer models 145
Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models 145
Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer 142
Mechanisms of resistance to mTOR inhibitors 142
RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges 140
Analysis of Health-Related Quality of Life Reporting in Phase III RCTs of Advanced Genitourinary Tumors 139
Paraneoplastic sensitive neuropathy associated with anti-hu antibodies in a neuroendocrine tumor of duodenum: a case report. 139
The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models. 139
Inadequate health-related quality of life assessment and reporting in phase III clinical trials of immune checkpoint inhibitors in solid cancers: a systematic review 139
P0081 Src inhibitors act through different mechanisms to cooperate with EGFR or MEK inhibitors in NSCLC models sensitive or resistant to erlotinib 138
A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer 138
Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions 137
Tumour microenvironment and immune evasion in EGFR addicted NSCLC: Hurdles and possibilities 136
Early assessment of IL8 and PD1+ Treg predicts response and guides treatment monitoring in cemiplimab-treated cutaneous squamous cell carcinoma 135
Insight on the Role of Leptin: A Bridge from Obesity to Breast Cancer 135
Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers 134
Role of FGFR3 in bladder cancer: Treatment landscape and future challenges 133
Mechanisms of lapatinib resistance in HER2-driven breast cancer 131
KRAS mutations in advanced non-small cell lung cancer: From biology to novel therapeutic strategies 129
SPHINGOSINE KINASE 1 (SPHK1) CONTRIBUTES TO RESISTANCE TO EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITORS IN COLORECTAL CANCER MODELS 129
Powerful anti-tumor and anti-angiogenic activity of a new anti-vascular endothelial growth factor receptor 1 peptide in colorectal cancer models 129
A Phase Ib Study of Alpelisib (BYL719), a PI3Ka-Specific Inhibitor, with Letrozole in ERþ/HER2 Metastatic Breast Cancer 129
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. 129
Predictors of outcomes in patients with EGFR-mutated non-small cell lung cancer receiving EGFR tyrosine kinase inhibitors: A systematic review and meta-analysis 129
How can we manage the cardiac toxicity of immune checkpoint inhibitors? 129
Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells 128
Tumor-to-tumor metastasis: breast cancer metastatic to thymic epithelial tumor. 128
Cardiovascular toxicities of immune therapies for cancer - a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology 128
Combined blockade of mTOR and p21-activated kinases pathways prevents tumour growth in KRAS-mutated colorectal cancer 127
Epidermal growth factor receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models. 127
Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial. 126
FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study 126
ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4/6 inhibitors 125
Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents 123
From biology to therapy: Improvements of therapeutic options in Lung cancer 122
Health-related quality of life is underestimated and underreported in phase III clinical trials in NSCLC 121
EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer 120
The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer 119
Activating PIK3CA mutations induce an epidermal growth factor receptor (EGFR)/extracellular signal-regulated Kinase (ERK) paracrine signaling axis in basal-like breast cancer 119
Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma. 117
The broad spectrum of cardiotoxicities from immunotherapies 115
FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR+) Breast Cancer. 114
Overexpression of CCL-20 and CXCL-8 genes enhances tumor escape and resistance to cemiplimab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with locally advanced and metastatic cutaneous squamous cell carcinoma 111
Sphingosine Kinase 1 (SphK1) overespression contributes to cetuximab resistance in human colrectal cancer. 111
FGFR1 associates with gene promoters and regulates gene transcription: Implications for endocrine resistance in ER+/FGFR1-amplified breast cancer 105
Association of FGFR1 with ERαmaintains ligand-independent ER transcription and mediates resistance to estrogen deprivation in ER+ breast cancer 104
Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers 103
Analysis of phase III clinical trials in metastatic NSCLC to assess the correlation between QoL results and survival outcomes 102
Cardio-Oncology Challenges in Elderly Patients 99
INHIBITION OF CANCER CELL GROWTH AND INVASION BY TARGETING C-SRC IN BREAST CANCER MODELS RESISTANT TO ANTI-HER2 DRUGS 98
Blinded independent central review versus local investigator assessment of PFS in RCTs of immunotherapy in advanced cancers: A systematic review and meta-analysis 97
Everolimus plus long-acting somatostatin analogs in thymic epithelial malignancies. 96
CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2- Metastatic Breast Cancer 92
Comprehensive Review on the Clinical Relevance of Long Non-Coding RNAs in Cutaneous Melanoma 90
AP1-mediated reprogramming of EGFR expression triggers resistance to BLU-667 and LOXO-292 in RET-rearranged tumors 84
Correction: Association of FGFR1 with ERA maintains ligand-independent ER transcription and mediates resistance to estrogen deprivation in ER þ breast cancer (Clinical Cancer Research (2019)23 (6138–6150) Doi:10.1158/1078-0432.CCR-17-1232) 82
Correction: ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4/6 inhibitors (Clinical Cancer Research (2018) 24 (2517–29) DOI: 10.1158/1078-0432.CCR-17-2904) 80
Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer. 80
Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer 80
Prostate-specific Antigen at 3 Months as a Predictor of Radiologic Progression-free Survival in Metastatic Hormone-sensitive Prostate Cancer Treated with Apalutamide: Analysis of 633 Patients in a Real-world Database 77
Clinical Outcomes and Prognostic Factors in Patients With Penile Carcinoma: A Sub-Analysis From Meet-URO 23 (I-RARE) Registry Study 77
Nuclear FGFR1 regulates gene transcription and promotes antiestrogen resistance in ERþ breast cancer 76
Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study 75
FGFR signaling and endocrine resistance in breast cancer: Challenges for the clinical development of FGFR inhibitors 74
Treatment of triple-negative breast cancer with TORC1/2 inhibitors sustains a drug-resistant and notch-dependent cancer stem cell population 72
Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2 72
Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4/6 inhibition in ER-positive breast cancer 70
FGFR1 Antibody Validation and Characterization of FGFR1 Protein Expression in ER+ Breast Cancer 69
An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression. 68
Malignant granular cell tumor of chest wall: a case report 67
Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study) 66
Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 Project 61
Early Identification and Management of Patients with Rash on Apalutamide 59
PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer 59
Discontinuation of anti-PD1 in advanced melanoma: an observational retrospective study from the Italian Melanoma Intergroup 55
Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance 54
Totale 11.075
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.604
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.604
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021100 0 0 0 0 0 0 0 0 0 27 44 29
2021/2022371 8 0 10 14 5 10 4 11 58 55 84 112
2022/2023628 63 38 31 28 69 76 15 58 88 92 42 28
2023/2024569 15 60 112 41 26 75 25 61 17 12 87 38
2024/20253.083 102 143 4 73 96 190 320 235 172 367 1.136 245
2025/20265.690 590 532 806 542 902 251 682 307 752 326 0 0
Totale 11.075